AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
Status:
Completed
Trial end date:
2019-11-20
Target enrollment:
Participant gender:
Summary
RATIONALE: AT9283 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of AT9283 in children
and adolescents with relapsed and refractory solid tumors.